Optimizing Cholesterol Treatment in Patients With Muscle Complaints

Journal of the American College of Cardiology

Volumn 70, Issue 10, 2017, Pages 1290-1301

  Rosenson, Robert S ^a   Baker, Steven ^b   Banach, Maciej ^c,d   Borow, Kenneth M ^e   Braun, Lynne T ^f   Bruckert, Eric ^g   Brunham, Liam R ^h   Catapano, Alberico L ⁱ   Elam, Marshall B ^j   Mancini, G B John ^k   Moriarty, Patrick M ^l   Morris, Pamela B ^m   Muntner, Paul ⁿ   Ray, Kausik K ^o   Stroes, Erik S ^p   Taylor, Beth A ^q,r   Taylor, Valerie H ^s   Watts, Gerald F ^t   Thompson, Paul D ^r  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d UNIVERSITY OF ZIELONA GÓRA   (Poland)

^e Outcomes and Adherence Program   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^m MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁿ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^o IMPERIAL COLLEGE LONDON   (United Kingdom)

^p ACADEMIC MEDICAL CENTER   (Netherlands)

^q UNIVERSITY OF CONNECTICUT   (United States)

^r HARTFORD HOSPITAL   (United States)

^s UNIVERSITY OF TORONTO   (Canada)

^t ROYAL PERTH HOSPITAL   (Australia)

more..

Author keywords

cardiovascular disease; low density lipoprotein; myalgia; myopathy; statin intolerance

Indexed keywords

ALIROCUMAB; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSENSUS; CORONARY ARTERY ATHEROSCLEROSIS; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG RECHALLENGE; DRUG SCREENING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENETIC VARIABILITY; HEALTH CARE COST; HUMAN; LEARNING ALGORITHM; LIFESTYLE MODIFICATION; MUSCLE DISEASE; MUSCLE FUNCTION; MUSCULOSKELETAL DISEASE ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STANDARDIZATION; STATIN ASSOCIATED MUSCLE SYMPTOM CLINICAL INDEX; STATIN MYALGIA CLINICAL INDEX; TREATMENT REFUSAL; BLOOD; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG EFFECTS; RISK FACTOR; SKELETAL MUSCLE;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SKELETAL; MUSCULAR DISEASES; RISK FACTORS;

EID: 85028514852     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.07.752     Document Type: Review

References (75)

1. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:Pt B (2014), 2889–2934.
2. Catapano, A.L., Graham, I., De Backer, G., et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Atherosclerosis 253 (2016), 281–344.
3. Baigent, C., Keech, A., Kearney, P.M., et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
4. McConnachie, A., Walker, A., Robertson, M., et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Eur Heart J 35 (2014), 290–298.
5. Collins, R., Reith, C., Emberson, J., et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388 (2016), 2532–2561.
6. Gupta, A., Thompson, D., Whitehouse, A., et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 389 (2017), 2473–2481.
7. Bruckert, E., Hayem, G., Dejager, S., Yau, C., Bégaud, B., Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther 19 (2005), 403–414.
8. Patel, J., Marin, S.S., Banach, M., Expert opinion: the therapeutic challenges faced by statin intolerance. Exp Opin Pharmacother 17 (2016), 1497–1507.
9. Colantonio, L.D., Huang, L., Monda, K.L., et al. Adherence to high intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries. JAMA Cardiol, 2017 Apr 19 [E-pub ahead of print].
10. Moriarty, P.M., Jacobson, T.A., Bruckert, E., et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol 8 (2014), 554–561.
11. Nissen, S.E., Stroes, E., Dent-Acosta, R.E., et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 315 (2016), 1580–1590.
12. Serban, M.C., Colantonio, L.D., Manthripragada, A., et al. Statin intolerance and risk for recurrent myocardial infarction, coronary heart disease events and all-cause mortality following hospital discharge after myocardial infarction among Medicare beneficiaries. J Am Coll Cardiol 69 (2017), 1386–1395.
13. Graham, J.H., Sanches, R.J., Sassen, J.J., Mallya, U.G., Panaccio, M.P., Evans, M.A., Clinical and economic consequences of statin intolerance in the United States: results from an integrated health system. J Clin Lipidol 11 (2017), 70–79.
14. Colantonio, L.D., Kent, S.T., Huang, L., et al. Algorithms to identify statin intolerance in Medicare administrative claim data. Cardiovasc Drugs Ther 30 (2016), 525–533.
15. Schulman, K.L., Lamerato, L.E., Dalal, M.R., et al. Development and validation of algorithms to identify statin Intolerance in a US administrative database. Value Health 19 (2016), 852–860.
16. Rosenson, R.S., Baker, S.K., Jacobson, T.A., Kopecky, S.L., Parker, B.A., The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 8:Suppl (2014), S58–S71.
17. Stroes, E.S., Thompson, P.D., Corsini, A., et al., European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 36 (2015), 1012–1022.
18. Banach, M., Rizzo, M., Toth, P.P., et al. Statin intolerance: an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 11 (2015), 1–23.
19. Mancini, G.B., Baker, S., Bergeron, J., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol 32:Suppl (2016), S35–S65.
20. Lloyd-Jones, D.M., Morris, P.B., Ballantyne, C.M., et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 68 (2016), 92–125.
21. Stulc, T., Ceska, R., Gotto, A.M. Jr., Statin intolerance: the clinician's perspective. Curr Atheroscler Rep, 17, 2015, 69.
22. Buettner, C., Davis, R.B., Leveille, S.G., Mittleman, M.A., Mukamal, K.J., Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 23 (2008), 1182–1186.
23. Parker, B.A., Capizzi, J.A., Grimaldi, A.S., et al. Effect of statins on skeletal muscle function. Circulation 127 (2013), 96–103.
24. Tobert, J.A., Newman, C.B., The nocebo effect in the context of statin intolerance. J Clin Lipidol 10 (2016), 739–747.
25. Joy, T.R., Monjed, A., Zou, G.Y., Hegele, R.A., McDonald, C.G., Mahon, J.L., N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med 160 (2014), 301–310.
26. Rosenson, R.S., Miller, K., Bayliss, M., et al. The Statin Myalgia Clinical Index (SMCI): Revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther 31 (2017), 179–186.
27. Taylor, B.A., Lorson, L., White, C.M., Thompson, P.D., A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 238 (2015), 329–335.
28. Taylor, B.A., Sanchez, R.J., Jacobson, T.A., et al. Application of the Statin Associated Muscle Symptoms Clinical Index (SAMS-CI) to a randomized controlled trial on statin myopathy. J Am Coll Cardiol, 2017 In press.
29. Wu, J.S., Buettner, C., Smithline, H., Ngo, L.H., Greenman, R.L., Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications. Muscle Nerve 43 (2011), 76–81.
30. Link, E., Parish, S., Armitage, J., et al., SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med 359 (2008), 789–799.
31. Voora, D., Shah, S.H., Spasojevic, I., et al. The SLCO1B15 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54 (2009), 1609–1616.
32. Donnelly, L.A., Doney, A.S., Tavendale, R., et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 89 (2011), 210–216.
33. Mammen, A.L., Statin-associated autoimmune myopathy. N Engl J Med 374 (2016), 664–669.
34. Hovingh, G.K., Gandra, S.R., McKendrick, J., et al. Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey. Atherosclerosis 245 (2016), 111–117.
35. Rosenson, R.S., Gandra, S.R., McKendrick, J., et al. Identification and management of statin-associated symptoms in clinical practice: extension of a clinical survey to 12 further countries. Cardiovasc Drugs Ther 31 (2017), 185–195.
36. Tanner, R.M., Safford, M.M., Monda, K.L., et al. Primary care physician perspectives on barriers to statin treatment. Cardiovasc Drugs Ther, 2017 Jul 14 [E-pub ahead of print].
37. Tanner R, Colantonio L, Safford L, et al. Prevalence and correlates of statin side effects and willingness to be rechallenged on a statin: data from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Paper presented at: ACC.17, March 17, 2017; Washington, DC.
38. Schachter, M., Clinical and pharmacokinetic properties of statins. Fundam Clin Pharmacol 19 (2005), 117–125.
39. Wiggins, B.S., Saseen, J.J., Page, R.L. 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation 134 (2016), e468–e495.
40. Algharably, E.A., Filler, I., Rosenfeld, S., Grabowski, K., Kreutz, R., Statin intolerance: a question of definition. Exp Opin Drug Saf 16 (2017), 55–63.
41. Stroes, E., Colquhoun, D., Sullivan, D., et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 63 (2014), 2541–2548.
42. Visser, M.E., Wagener, G., Baker, B.F., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 33 (2012), 1142–1149.
43. Glueck, C.J., Abuchaibe, C., Wang, P., Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Med Hypotheses 77 (2011), 658–661.
44. Khayznikov, M., Hemachrandra, K., Pandit, R., Kumar, A., Wang, P., Glueck, C.J., Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation. N Am J Med Sci 7 (2015), 86–93.
45. Sullivan, D., Olsson, A.G., Scott, R., et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308 (2012), 2497–2506.
46. Ganga, H.V., Slim, H.B., Thompson, P.D., A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 168 (2014), 6–15.
47. Mampuya, W.M., Frid, D., Rocco, M., et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 166 (2013), 597–603.
48. Zhang, H., Plutzky, J., Skentzos, S., et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 158 (2013), 526–534.
49. Awad, K., Mikhalidis, D.P., Toth, P.P., et al. Efficacy and safety of alternate-day versus daily dosing of statins: a systematic review and meta-analysis. Cardiovasc Drugs Ther, 2017 Jul 24 [E-pub ahead of print].
50. Rivers, S.M., Kane, M.P., Busch, R.S., Bakst, G., Hamilton, R.A., Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 13 (2007), 11–16.
51. Marazzi, G., Pelliccia, F., Campolongo, G., et al. Usefulness of nutraceuticals (Armolipid Plus) versus ezetimibe and combination in statin-intolerant patients with dyslipidemia with coronary heart disease. Am J Cardiol 116 (2015), 1798–1801.
52. Wierzbicki, A.S., Doherty, E., Lumb, P.J., Chik, G., Crook, M.A., Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 21 (2005), 333–338.
53. Stein, E.A., Ballantyne, C.M., Windler, E., et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 101 (2008), 490–496.
54. Athyros, V.G., Tziomalos, K., Kakafika, A.I., Koumaras, H., Karagiannis, A., Mikhailidis, D.P., Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 101 (2008), 483–485.
55. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al., IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
56. Farnier, M., Bonnefous, F., Debbas, N., Irvine, A., Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 154 (1994), 441–449.
57. Sacks, F.M., Carey, V.J., Fruchart, J.C., Combination lipid therapy in type 2 diabetes. N Engl J Med 363 (2010), 692–694.
58. Ginsberg, H.N., Elam, M.B., Lovato, L.C., et al., ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 36 (2010), 1563–1574.
59. Canner, P.L., Berge, K.G., Wenger, N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol, 1986, 1245–1255.
60. Stein, E.A., Raal, F., Future directions to establish lipoprotein(a) as a treatment for atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther 30 (2016), 101–108.
61. Boden, W.E., Probstfield, T., Anderson, T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
62. HPS-2 THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371 (2014), 203–212.
63. Pinkosky, S.L., Newton, R.S., Day, E.A., et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun, 7, 2016, 13457.
64. Thompson, P.D., Rubino, J., Janik, M.J., et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol 9 (2015), 295–304.
65. Thompson, P.D., MacDougall, D.E., Newton, R.S., et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL-C in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol 10 (2016), 556–567.
66. Cicero, A.F., Morbini, M., Bove, M., et al. Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic. Curr Med Res Opin 8 (2016), 1–6.
67. Becker, D.J., Gordon, R.Y., Halbert, S.C., French, B., Morris, P.B., Rader, D.J., Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 150 (2009), 830–839.
68. Halbert, S.C., French, B., Gordon, R.Y., et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 105 (2010), 198–204.
69. Banach, M., Serban, C., Ursoniu, S., et al., Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Statin therapy and plasma coenzyme Q10 concentrations–a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res 99 (2015), 329–336.
70. Michalska-Kasiczak, M., Sahebkar, A., Mikhailidis, D.P., et al., Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statin-associated myalgia: a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 178 (2015), 111–116.
71. Kang, J.H., Nguyen, Q.-N., Mutka, J., Le, Q.A., Rechallenging statin therapy in veterans with statin-induced myopathy post vitamin D replenishment. J Pharm Pract, 2016 Oct 24 [E-pub ahead of print].
72. Sahebkar, A., Saboni, N., Pirro, M., Banach, M., Curcumin: an effective adjunct in patients with statin-associated muscle symptoms?. J Cachexia Sarcopenia Muscle 8 (2017), 19–24.
73. Arca, M., Pigna, G., Treating statin-intolerant patients. Diabetes Metab Syndr Obes 4 (2011), 155–166.
74. Korhonen, M.J., Pentti, J., Hartikainen, J., Kivimäki, M., Vahtera, J., Somatic symptoms of anxiety and nonadherence to statin therapy. Int J Cardiol 214 (2016), 493–499.
75. Cohen, J.D., Brinton, E.A., Ito, M.K., Jacobson, T.A., Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 6 (2012), 208–215.